Stock Performance and Price Targets - Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) gained 2 9% over the past four weeks closing at $32 83 with a potential upside of 112 8% based on the mean price target of $69 87 [1] - The mean estimate includes 15 short-term price targets with a standard deviation of $21 22 indicating variability among analysts The lowest estimate is $24 (26 9% decline) while the most optimistic target is $100 (204 6% surge) [2] - A low standard deviation suggests greater agreement among analysts which could be a good starting point for further research [7] Analysts' Price Targets and Earnings Estimates - Analysts' growing optimism over IMCR's earnings prospects is supported by strong agreement in revising EPS estimates higher which historically correlates with near-term stock price movements [9] - The Zacks Consensus Estimate for the current year increased by 44% over the past month with eight positive revisions and no negative revisions [10] - IMCR holds a Zacks Rank 1 (Strong Buy) placing it in the top 5% of over 4 000 stocks based on earnings estimate factors indicating strong potential upside [11] Limitations of Price Targets - Price targets can mislead investors as empirical research shows they rarely predict actual stock price movements accurately [5] - Analysts may set overly optimistic price targets to generate interest in stocks often influenced by business incentives rather than unbiased analysis [6] - Investors should not rely solely on price targets for investment decisions as they should be treated with skepticism [8]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ZIM Integrated Shipping Services Ltd. (ZIM) : This container shipping provider has seen the Zacks Consensus Estimate for its current year earnings increasing 41.7% over the last 60 days.monday.com Ltd. (MNDY) : This software development company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.9% over the last 60 days.Rush Street Interactive, Inc. (RSI) : This online casino and sports betting company has ...

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the last trading session at $34.31, gaining 11.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $72.93 indicates an 112.6% upside potential.The average comprises 15 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $18.74. While the lowest estimate indicates a decline of 30.1% fro ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November.                   Guggenheim Securities Heal ...

Exhibit 99.1 Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | --- | --- | |-------- ...

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earl ...

Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estima ...

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pretreated, platinum-resistant ovarian cancer patients T cell fitness gene expression signature in blood is an important parameter of clinical activity for tebentafusp in uveal melanoma and for brenetafusp across different tumor types (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., ...

Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2024 Cantor Global ...